Anti-c-Myc Antibody, clone 7E18, ZooMAb^® Rabbit Monoclonal

rabbit (recombinant)

expressed in HEK 293 cells

unconjugated

purified antibody

primary antibodies

7E18, monoclonal
recombinant monoclonal

ZooMAb^® learn more

lyophilized

calculated mol wt 48.8 kDa
observed mol wt ~55 kDa

mouse, human

antibody small pack of 25 μL

Waste Prevention
Designing Safer Chemicals
Design for Energy Efficiency
Learn more about the Principles of Green Chemistry.

recombinant expression
Learn more about Antibody Enhanced Validation

gene knockdown: suitable using 1:1,000
immunocytochemistry: 1:100-1:250
immunohistochemistry: suitable using 1:100
western blot: suitable using 1:1,000

IgG

P01106

ambient

2-8℃

human ... MYC;BHLHE39(4609)

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.

Learn more about ZooMAb here.

Clone 7E18 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects human Myc proto-oncogene protein (c-Myc).

GST/His-tagged recombinant fragment corresponding to 109 amino acids from the internal region of human c-Myc.

Anti-c-Myc, clone 7E18, ZooMAb, Cat. No. ZRB1003-25UL, is a recombinant Rabbit Monoclonal Antibody that specifically targets c-Myc proto-oncogene and has been tested for use in Immunocytochemistry, Immunohistochemistry, RNAi/siRNA/Gene Knockdown, and Western Blotting,
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected c-Myc in human kidney, mouse testis, and human cervical cancer tissue sections.

RNAi/siRNA/Gene Knockdown Analysis: A 1:1000 dilution from a representative lot detected c-Myc in lysate from wild-type HEK293 cells, but not in HEK293 cells with c-myc knocked out using CRISPR.

Immunocytochemistry Analysis: A 1:250 dilution from a representative lot detected Myc proto-oncogene protein in HeLa, A431, HUVEC, and NIH 3T3 cell lines.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

300 μg/mL after reconstitution at 25 μL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Myc proto-oncogene protein (UniProt: P01106; also known as Class E basic helix-loop-helix protein 39, bHLHe39, Proto-oncogene c-Myc, Transcription factor p64) is encoded by the MYC (also known as BHLHE39) gene (Gene ID: 4609) in human. c-Myc is a transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5′-CAC[GA]TG-3′. It regulates the expression of multiple genes involved in apoptosis, cell differentiation and cell proliferation. c-Myc is shown to be critically involved in the regulation of several growth promoting signaling pathways and is considered as an immediate early response gene that is downstream of many ligand-membrane receptor complexes. Its expression is reported to be tightly regulated by several transcriptional regulatory motifs within its proximal promoter region. Phosphorylation of c-Myc by serine/threonine kinase PIM2 at serine 329 is reported to lead to its stabilization. Active c-Myc is coupled to the MAX protein via its C-terminal helix-loop-helix leucine zipper (bHLHLZ) domain (aa 413-434) and this heterodimer interacts with a number of other transcription-related proteins. In normal cells its expression and function are regulated by developmental or mitogenic signals. c-Myc mRNA has a very short half-life and in the absence of positive regulatory signals there is a significant reduction in its transcription leading to low c-Myc protein levels that does not have any proliferative drive. However, in tumor cells its levels are increased either via mutations or induction via upstream oncogenic pathways. Mutations in c-Myc gene are known to cause B-cell chronic lymphocytic leukemia and Burkitt lymphoma. Over-expression of c-Myc has been reported in about 40% tumors. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Miller, DM et al., (2012). Clin. Cancer Res. 18(20); 5546-5553).

Recommend storage of lyophilized product at 2-8℃; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8℃, or -20℃ for long term storage. Avoid repeated freeze-thaws.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

11 - Combustible Solids

WGK 1